ExcelMale
Menu
Home
What's new
Latest activity
Forums
New posts
Search forums
What's new
New posts
Latest activity
Videos
Lab Tests
Doctor Finder
Buy Books
About Us
Men’s Health Coaching
Log in
Register
What's new
Search
Search
Search titles only
By:
New posts
Search forums
Menu
Log in
Register
Navigation
Install the app
Install
More options
Contact us
Close Menu
Forums
ExcelFemale
HRT in Women
Low-Dose Testosterone Augmentation for Antidepressant-Resistant Major Depressive Disorder in Women
JavaScript is disabled. For a better experience, please enable JavaScript in your browser before proceeding.
You are using an out of date browser. It may not display this or other websites correctly.
You should upgrade or use an
alternative browser
.
Reply to thread
Message
<blockquote data-quote="madman" data-source="post: 182313" data-attributes="member: 13851"><p><strong>Low-Dose Testosterone Augmentation for Antidepressant-Resistant Major Depressive Disorder in Women: <span style="color: rgb(184, 49, 47)">An 8-Week Randomized Placebo-Controlled Study </span></strong></p><p><strong></strong></p><p><strong></strong></p><p><strong>Objective:</strong> Low-dose testosterone has been shown to improve depression symptom severity, fatigue, and sexual function in small studies in women not formally diagnosed with major depressive disorder. The authors sought to determine whether adjunctive low-dose transdermal testosterone improves depression symptom severity, fatigue, and sexual function in women with antidepressant-resistant major depression. A functional MRI (fMRI) substudy examined effects on activity in the anterior cingulate cortex (ACC), a brain region important in mood regulation.</p><p></p><p><strong>Methods:</strong> The authors conducted an 8-week randomized double-blind placebo-controlled trial of adjunctive testosterone cream in 101 women, ages 21–70, with antidepressant-resistant major depression. The primary outcome measure was depression symptom severity as assessed by the Montgomery-Åsberg Depression Rating Scale (MADRS). Secondary endpoints included fatigue, sexual function, and safety measures. The primary outcome of the fMRI substudy (N=20) was change in ACC activity.</p><p></p><p><strong>Results:</strong> The participants’ mean age was 47 years (SD=14) and their mean baseline MADRS score was 26.6 (SD=5.9). Eighty-seven (86%) participants completed 8 weeks of treatment. MADRS scores decreased in both study arms from baseline to week 8 (testosterone arm: from 26.8 [SD=6.3] to 15.3 [SD=9.6]; placebo arm: from 26.3 [SD=5.4] to 14.4 [SD=9.3]), with no significant difference between groups. Improvement in fatigue and sexual function did not differ between groups, nor did side effects. fMRI results showed a relationship between ACC activation and androgen levels before treatment but no difference in ACC activation with testosterone compared with placebo.</p><p></p><p><strong>Conclusions:</strong> <em><span style="color: rgb(184, 49, 47)">Adjunctive transdermal testosterone, although well-tolerated, was not more effective than placebo in improving symptoms of depression, fatigue, or sexual dysfunction. Imaging in a subset of participants demonstrated that testosterone did not result in greater activation of the ACC. </span></em></p><p></p><p></p><p><strong>CONCLUSIONS </strong></p><p></p><p><em><span style="color: rgb(184, 49, 47)"><strong>This rigorously designed double-blind clinical trial did not find significant group differences between adjunctive low dose transdermal testosterone and placebo for antidepressant augmentation in women with treatment-resistant major depression and had a high placebo response rate.</strong></span></em> <em><span style="color: rgb(184, 49, 47)"><strong>Low-dose testosterone was well tolerated but failed to differentially affect overall depression symptom severity, fatigue, or sexual dysfunction in women treated for 8 weeks with dosages titrated to achieve blood levels near the upper end of the normal reference range. Additionally, testosterone did not result in greater activity compared with placebo in a brain region (ACC and PCC) implicated in major depression etiopathology.</strong></span></em> <strong><em><span style="color: rgb(44, 130, 201)"><u>Based on our findings and the results of several other recent clinical trials, we conclude that the addition of low-dose testosterone to ongoing, ineffective antidepressant medications should not be recommended for women with major depression</u>. These negative results are important given the number of women who use off-label male-branded or compounded testosterone. Further studies of adjunctive testosterone in antidepressant-resistant major depression using strategies designed to reduce placebo effects may be warranted. </span></em></strong></p><p></p><p></p><p></p><p></p><p></p><p><span style="color: rgb(184, 49, 47)"><em>* Limitations of this study were those inherent in all blinded clinical trials of a disorder characterized by symptom heterogeneity and response vulnerable to placebo effect, in this case, major depression. It is possible that a more homogeneous population of postmenopausal women with lower levels of testosterone at baseline would allow the detection of differences in adjunctive testosterone compared with placebo. Moreover, we cannot rule out type II error in the context of a higher than expected placebo response.</em></span></p></blockquote><p></p>
[QUOTE="madman, post: 182313, member: 13851"] [B]Low-Dose Testosterone Augmentation for Antidepressant-Resistant Major Depressive Disorder in Women: [COLOR=rgb(184, 49, 47)]An 8-Week Randomized Placebo-Controlled Study [/COLOR] Objective:[/B] Low-dose testosterone has been shown to improve depression symptom severity, fatigue, and sexual function in small studies in women not formally diagnosed with major depressive disorder. The authors sought to determine whether adjunctive low-dose transdermal testosterone improves depression symptom severity, fatigue, and sexual function in women with antidepressant-resistant major depression. A functional MRI (fMRI) substudy examined effects on activity in the anterior cingulate cortex (ACC), a brain region important in mood regulation. [B]Methods:[/B] The authors conducted an 8-week randomized double-blind placebo-controlled trial of adjunctive testosterone cream in 101 women, ages 21–70, with antidepressant-resistant major depression. The primary outcome measure was depression symptom severity as assessed by the Montgomery-Åsberg Depression Rating Scale (MADRS). Secondary endpoints included fatigue, sexual function, and safety measures. The primary outcome of the fMRI substudy (N=20) was change in ACC activity. [B]Results:[/B] The participants’ mean age was 47 years (SD=14) and their mean baseline MADRS score was 26.6 (SD=5.9). Eighty-seven (86%) participants completed 8 weeks of treatment. MADRS scores decreased in both study arms from baseline to week 8 (testosterone arm: from 26.8 [SD=6.3] to 15.3 [SD=9.6]; placebo arm: from 26.3 [SD=5.4] to 14.4 [SD=9.3]), with no significant difference between groups. Improvement in fatigue and sexual function did not differ between groups, nor did side effects. fMRI results showed a relationship between ACC activation and androgen levels before treatment but no difference in ACC activation with testosterone compared with placebo. [B]Conclusions:[/B] [I][COLOR=rgb(184, 49, 47)]Adjunctive transdermal testosterone, although well-tolerated, was not more effective than placebo in improving symptoms of depression, fatigue, or sexual dysfunction. Imaging in a subset of participants demonstrated that testosterone did not result in greater activation of the ACC. [/COLOR][/I] [B]CONCLUSIONS [/B] [I][COLOR=rgb(184, 49, 47)][B]This rigorously designed double-blind clinical trial did not find significant group differences between adjunctive low dose transdermal testosterone and placebo for antidepressant augmentation in women with treatment-resistant major depression and had a high placebo response rate.[/B][/COLOR][/I] [I][COLOR=rgb(184, 49, 47)][B]Low-dose testosterone was well tolerated but failed to differentially affect overall depression symptom severity, fatigue, or sexual dysfunction in women treated for 8 weeks with dosages titrated to achieve blood levels near the upper end of the normal reference range. Additionally, testosterone did not result in greater activity compared with placebo in a brain region (ACC and PCC) implicated in major depression etiopathology.[/B][/COLOR][/I] [B][I][COLOR=rgb(44, 130, 201)][U]Based on our findings and the results of several other recent clinical trials, we conclude that the addition of low-dose testosterone to ongoing, ineffective antidepressant medications should not be recommended for women with major depression[/U]. These negative results are important given the number of women who use off-label male-branded or compounded testosterone. Further studies of adjunctive testosterone in antidepressant-resistant major depression using strategies designed to reduce placebo effects may be warranted. [/COLOR][/I][/B] [COLOR=rgb(184, 49, 47)][I]* Limitations of this study were those inherent in all blinded clinical trials of a disorder characterized by symptom heterogeneity and response vulnerable to placebo effect, in this case, major depression. It is possible that a more homogeneous population of postmenopausal women with lower levels of testosterone at baseline would allow the detection of differences in adjunctive testosterone compared with placebo. Moreover, we cannot rule out type II error in the context of a higher than expected placebo response.[/I][/COLOR] [/QUOTE]
Insert quotes…
Verification
Post reply
Share this page
Facebook
Twitter
Reddit
Pinterest
Tumblr
WhatsApp
Email
Share
Link
Sponsors
Forums
ExcelFemale
HRT in Women
Low-Dose Testosterone Augmentation for Antidepressant-Resistant Major Depressive Disorder in Women
This site uses cookies to help personalise content, tailor your experience and to keep you logged in if you register.
By continuing to use this site, you are consenting to our use of cookies.
Accept
Learn more…
Top